Shares of Bayer AG (OTCMKTS:BAYRY) have earned a consensus rating of “Hold” from the seven research firms that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating on the company.

BAYRY has been the topic of a number of recent analyst reports. ValuEngine raised Bayer from a “strong sell” rating to a “sell” rating in a research report on Monday, February 4th. JPMorgan Chase & Co. downgraded Bayer from an “overweight” rating to a “neutral” rating in a research report on Wednesday, January 2nd. Finally, Zacks Investment Research downgraded Bayer from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 23rd.

BAYRY stock traded down $0.05 during midday trading on Wednesday, hitting $18.80. 107,981 shares of the company’s stock were exchanged, compared to its average volume of 514,399. The firm has a market cap of $70.05 billion, a PE ratio of 9.89, a P/E/G ratio of 1.28 and a beta of 0.96. Bayer has a one year low of $16.58 and a one year high of $32.80. The company has a current ratio of 1.59, a quick ratio of 1.04 and a debt-to-equity ratio of 0.80.

Bayer (OTCMKTS:BAYRY) last issued its quarterly earnings results on Tuesday, November 13th. The company reported $0.35 EPS for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.06). The firm had revenue of $11.52 billion during the quarter, compared to the consensus estimate of $11.31 billion. Bayer had a net margin of 15.58% and a return on equity of 13.59%. On average, analysts forecast that Bayer will post 1.64 earnings per share for the current year.

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Recommended Story: What impact do institutional investors have on markets?

Analyst Recommendations for Bayer (OTCMKTS:BAYRY)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.